RxDoctor Payments Data

Valneo Buttari, MD

Internal Medicine · Mt Vernon, NYNPI 1770562530

Payments from drug & device makers

$5,261in general payments, 2019–2025

Across 49 payments — averaging $107.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$510
  • AbbVie$351
  • AstraZeneca$267
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$255
  • Genentech USA, Inc.$251
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,254100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,261 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,786
Medicare patients
130
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ergotamine-CaffeineErgotamine Tartrate/Caffeine145$151,440
LinzessLinaclotide243$143,923
XiidraLifitegrast167$134,145
EliquisApixaban144$120,545
TradjentaLinagliptin164$99,360
Combivent RespimatIpratropium/Albuterol Sulfate177$96,172
JardianceEmpagliflozin115$86,627
MyrbetriqMirabegron159$79,453
TrulicityDulaglutide50$76,785
VascepaIcosapent Ethyl177$67,686
Pimecrolimus102$53,411
BrilintaTicagrelor88$46,588
Dihydroergotamine Mesylate31$36,541
Advair HfaFluticasone Propion/Salmeterol76$36,516
Sucralfate117$33,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Combivent Respimat, Jardiance$250$282,159456 claims
AbbVieLinzess, Restasis, Creon, Lumigan$351$184,701305 claims
Lilly USA, LLCTrulicity$169$76,78550 claims
AstraZenecaBrilinta, Farxiga$267$65,921109 claims
Johnson & JohnsonXarelto$1,556$15,09813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mt Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →